Aytu Biopharma, Inc: Form 10-Q for the period ended Mar 31, 2025
Filed with the SEC on May 14, 2025 and accepted by EDGAR at May 14, 2025, 16:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-01-01 to 2025-03-31 | $18.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2024-07-01 to 2025-03-31 | $51.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-01-01 to 2025-03-31 | $5.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2024-07-01 to 2025-03-31 | $15.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-01-01 to 2025-03-31 | $12.8m | us-gaap:GrossProfit |
| Gross profit | 9 months2024-07-01 to 2025-03-31 | $35.6m | us-gaap:GrossProfit |
| Research and development | 3 months2025-01-01 to 2025-03-31 | $162.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-07-01 to 2025-03-31 | $1.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-01-01 to 2025-03-31 | $2.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-07-01 to 2025-03-31 | −$204.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-01-01 to 2025-03-31 | $900.0k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2024-07-01 to 2025-03-31 | $3.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-01-01 to 2025-03-31 | −$122.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-07-01 to 2025-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-01-01 to 2025-03-31 | $4.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-07-01 to 2025-03-31 | $6.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-01-01 to 2025-03-31 | $0.21 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-07-01 to 2025-03-31 | −$0.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-01-01 to 2025-03-31 | $0.65 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-07-01 to 2025-03-31 | $1.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-01-01 to 2025-03-31 | 8,204,453 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-07-01 to 2025-03-31 | 8,606,013 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-07-01 to 2025-03-31 | −$4.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-03-31 | $18.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-03-31 | $72.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-31 | $124.2m | us-gaap:Assets |
| Current liabilities | At period end2025-03-31 | $70.7m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2025-03-31 | $9.5m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2025-03-31 | $1.9m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2025-03-31 | $34.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-25-016833. Last ingested by Listed: Oct 27, 2026, 16:32 ET. Listed shows no prices and gives no investment advice.